|
1
|
Cooperberg MR, Cowan J, Broering JM and
Carroll PR: High-risk prostate cancer in the United States,
1990-2007. World J Urol. 26:211–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pagliarulo V, Bracarda S, Eisenberger MA,
Mottet N, Schröder FH, Sternberg CN and Studer UE: Contemporary
role of androgen deprivation therapy for prostate cancer. Eur Urol.
61:11–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu T, Wu LY, Fulton MD, Johnson JM and
Berkman CE: Prolonged androgen deprivation leads to downregulation
of androgen receptor and prostate-specific membrane antigen in
prostate cancer cells. Int J Oncol. 41:2087–2092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
5
|
Teo MY, Rathkopf DE and Kantoff P:
Treatment of advanced prostate cancer. Annu Rev Med. 70:479–499.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
FDA approves enzalutamide for
castration-resistant prostate cancer, . https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancerDecember
1–2021
|
|
7
|
Wengner AM, Scholz A and Haendler B:
Targeting DNA damage response in prostate and breast cancer. Int J
Mol Sci. 21:82732020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J,
Chowdhury S, et al: Enzalutamide in metastatic prostate cancer
before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim YS, Yi BR, Kim NH and Choi KC: Role of
the epithelial-mesenchymal transition and its effects on embryonic
stem cells. Exp Mol Med. 46:e1082014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
12
|
Jennbacken K, Gustavsson H, Welén K,
Vallbo C and Damber JE: Prostate cancer progression into androgen
independency is associated with alterations in cell adhesion and
invasivity. Prostate. 66:1631–1640. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vesuna F, van Diest P, Chen JH and Raman
V: Twist is a transcriptional repressor of E-cadherin gene
expression in breast cancer. Biochem Biophys Res Commun.
367:235–241. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vered M, Dayan D, Yahalom R, Dobriyan A,
Barshack I, Bello IO, Kantola S and Salo T: Cancer-associated
fibroblasts and epithelial-mesenchymal transition in metastatic
oral tongue squamous cell carcinoma. Int J Cancer. 127:1356–1362.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Randle DD, Clarke S, Henderson V and
Odero-Marah VA: Snail mediates invasion through uPA/uPAR and the
MAPK signaling pathway in prostate cancer cells. Oncol Lett.
6:1767–1773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uygur B and Wu WS: SLUG promotes prostate
cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol
Cancer. 10:1392011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Navarro P, Ruco L and Dejana E:
Differential localization of VE- and N-cadherins in human
endothelial cells: VE-cadherin competes with N-cadherin for
junctional localization. J Cell Biol. 140:1475–1484. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hatta K, Takagi S, Fujisawa H and Takeichi
M: Spatial and temporal expression pattern of N-cadherin cell
adhesion molecules correlated with morphogenetic processes of
chicken embryos. Dev Biol. 120:215–227. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Derycke LD and Bracke ME: N-cadherin in
the spotlight of cell-cell adhesion, differentiation,
embryogenesis, invasion and signalling. Int J Dev Biol. 48:463–476.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma T, Zhao Y, Wei K, Yao G, Pan C, Liu B,
Xia Y, He Z, Qi X, Li Z, et al: MicroRNA-124 functions as a tumor
suppressor by regulating CDH2 and epithelial-mesenchymal transition
in non-small cell lung cancer. Cell Physiol Biochem. 38:1563–1574.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van der Horst G, Bos L, van der Mark M,
Cheung H, Heckmann B, Clément-Lacroix P, Lorenzon G, Pelger RC,
Bevers RF and van der Pluijm G: Targeting of alpha-v integrins
reduces malignancy of bladder carcinoma. PLoS One. 9:e1084642014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Markou A, Lazaridou M, Paraskevopoulos P,
Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA,
Kroneis T, et al: Multiplex gene expression profiling of in vivo
isolated circulating tumor cells in high-risk prostate cancer
patients. Clin Chem. 64:297–306. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sandig M, Voura EB, Kalnins VI and Siu CH:
Role of cadherins in the transendothelial migration of melanoma
cells in culture. Cell Motil Cytoskeleton. 38:351–364. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanaka H, Kono E, Tran CP, Miyazaki H,
Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, et
al: Monoclonal antibody targeting of N-cadherin inhibits prostate
cancer growth, metastasis and castration resistance. Nat Med.
16:1414–1420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomita K, van Bokhoven A, van Leenders GJ,
Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin
switching in human prostate cancer progression. Cancer Res.
60:3650–3654. 2000.PubMed/NCBI
|
|
27
|
Jaggi M, Nazemi T, Abrahams NA, Baker JJ,
Galich A, Smith LM and Balaji KC: N-cadherin switching occurs in
high gleason grade prostate cancer. Prostate. 66:193–199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kregel S, Chen JL, Tom W, Krishnan V, Kach
J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ and
Griend DJV: Acquired resistance to the second-generation androgen
receptor antagonist enzalutamide in castration-resistant prostate
cancer. Oncotarget. 7:26259–26274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee GT, Rosenfeld JA, Kim WT, Kwon YS,
Palapattu G, Mehra R, Kim WJ and Kim IY: TCF4 induces enzalutamide
resistance via neuroendocrine differentiation in prostate cancer.
PLoS One. 14:e02134882019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pangestu NS, Chueakwon P, Talabnin K,
Khiaowichit J and Talabnin C: RNF43 overexpression attenuates the
wnt/β-catenin signalling pathway to suppress tumour progression in
cholangiocarcinoma. Oncol Lett. 22:8462021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang YH, Kuo HC, Yang YL and Wang FS:
MicroRNA-29a is a key regulon that regulates BRD4 and mitigates
liver fibrosis in mice by inhibiting hepatic stellate cell
activation. Int J Med Sci. 16:212–220. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bussemakers MJ, Van Bokhoven A, Tomita K,
Jansen CF and Schalken JA: Complex cadherin expression in human
prostate cancer cells. Int J Cancer. 85:446–450. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jennbacken K, Tesan T, Wang W, Gustavsson
H, Damber JE and Welén K: N-cadherin increases after androgen
deprivation and is associated with metastasis in prostate cancer.
Endocr Relat Cancer. 17:469–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nalla AK, Estes N, Patel J and Rao JS:
N-cadherin mediates angiogenesis by regulating monocyte
chemoattractant protein-1 expression via PI3K/Akt signaling in
prostate cancer cells. Exp Cell Res. 317:2512–2521. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao S, Zhao Z, Wu R, Wu L, Tian X and
Zhang Z: MicroRNA-194 regulates cell viability and apoptosis by
targeting CDH2 in prostatic cancer. Onco Targets Ther.
11:4837–4844. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang M, Ren D, Guo W, Huang S, Wang Z, Li
Q, Du H, Song L and Peng X: N-cadherin promotes
epithelial-mesenchymal transition and cancer stem cell-like traits
via ErbB signaling in prostate cancer cells. Int J Oncol.
48:595–606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mariotti A, Perotti A, Sessa C and Rüegg
C: N-cadherin as a therapeutic target in cancer. Expert Opin
Investig Drugs. 16:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and
N-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8:11182019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang YG, Luo Y, He DL, Li X, Zhang LL,
Peng T, Li MC and Lin YH: Role of Wnt/beta-catenin signaling
pathway in epithelial-mesenchymal transition of human prostate
cancer induced by hypoxia-inducible factor-1alpha. Int J Urol.
14:1034–1039. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: Acquisition of
epithelial-mesenchymal transition and cancer stem cell phenotypes
is associated with activation of the PI3K/Akt/mTOR pathway in
prostate cancer radioresistance. Cell Death Dis. 4:e8752013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liang J, Li Y, Daniels G, Sfanos K, De
Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, et al: LEF1
targeting EMT in prostate cancer invasion is regulated by miR-34a.
Mol Cancer Res. 13:681–688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen X, Cheng H, Pan T, Liu Y, Su Y, Ren
C, Huang D, Zha X and Liang C: mTOR regulate EMT through RhoA and
Rac1 pathway in prostate cancer. Mol Carcinog. 54:1086–1095. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Baygi ME, Soheili ZS, Essmann F, Deezagi
A, Engers R, Goering W and Schulz WA: Slug/SNAI2 regulates cell
proliferation and invasiveness of metastatic prostate cancer cell
lines. Tumour Biol. 31:297–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stylianou N, Lehman ML, Wang C, Fard AT,
Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS,
et al: A molecular portrait of epithelial-mesenchymal plasticity in
prostate cancer associated with clinical outcome. Oncogene.
38:913–934. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li J, Chong T, Wang Z, Chen H and Li H,
Cao J, Zhang P and Li H: A novel anti-cancer effect of resveratrol:
Reversal of epithelial-mesenchymal transition in prostate cancer
cells. Mol Med Rep. 10:1717–1724. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du Y, Long Q, Zhang L, Shi Y, Liu X, Li X,
Guan B, Tian Y, Wang X, Li L and He D: Curcumin inhibits
cancer-associated fibroblast-driven prostate cancer invasion
through MAOA/mTOR/HIF-1α signaling. Int J Oncol. 47:2064–2072.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vanacore D, Boccellino M, Rossetti S,
Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La
Mantia E, Piscitelli R, et al: Micrornas in prostate cancer: An
overview. Oncotarget. 8:50240–50251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lo UG, Yang D and Hsieh JT: The role of
microRNAs in prostate cancer progression. Transl Androl Urol.
2:228–241. 2013.PubMed/NCBI
|
|
50
|
Cochetti G, Rossi de Vermandois JA, Maulà
V, Giulietti M, Cecati M, Del Zingaro M, Cagnani R, Suvieri C,
Paladini A and Mearini E: Role of miRNAs in prostate cancer: Do we
really know everything? Urol Oncol. 38:623–635. 2020. View Article : Google Scholar : PubMed/NCBI
|
